- A combination of AstraZeneca Plc’s (NASDAQ: AZN) Imfinzi (durvalumab), tremelimumab, and chemotherapy has extended overall survival (OS) when used as a first-line treatment for stage IV (metastatic) non-small cell lung cancer (NSCLC).
- A final analysis of data from the POSEIDON Phase 3 study shows that the combination demonstrated a statistically significant and clinically meaningful OS benefit versus chemotherapy alone.
- The trial also tested a combination of Imfinzi plus chemotherapy, which, while showing a statistically significant improvement in progression-free survival (PFS) versus chemotherapy, failed to improve OS significantly.
- Each combination demonstrated an acceptable safety profile, and no new safety signals were identified.
- The data will be presented at a forthcoming medical meeting.
- Price Action: AZN shares are up 0.62% at $53.81 during the market trading session on the last check Friday.
Truist Securities Maintains Buy on Broadcom, Lowers Price Target to $630
Truist Securities analyst William Stein maintains Broadcom (NASDAQ:AVGO) with a Buy and lowers the price target from $658 to $630.
